hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Recreational === MDMA is often considered the drug of choice within the rave culture and is also used at clubs, festivals, and house parties. In the rave environment, the sensory effects of music and lighting are often highly synergistic with the drug. The psychedelic amphetamine quality of MDMA offers multiple appealing aspects to users in the rave setting. Some users enjoy the feeling of mass communion from the inhibition-reducing effects of the drug, while others use it as party fuel because of the drug's stimulatory effects. MDMA is used less often than other stimulants, typically less than once per week. MDMA is sometimes taken in conjunction with other psychoactive drugs such as LSD, psilocybin mushrooms, 2C-B, and ketamine. The combination with LSD is called "candy-flipping". The combination with 2C-B is called "nexus flipping". For this combination, most people take the MDMA first, wait until the peak is over, and then take the 2C-B. MDMA is often co-administered with alcohol, methamphetamine, and prescription drugs such as SSRIs with which MDMA has several drug-drug interactions. Three life-threatening reports of MDMA co-administration with ritonavir have been reported; with ritonavir having severe and dangerous drug-drug interactions with a wide range of both psychoactive, anti-psychotic, and non-psychoactive drugs.
== Overview and assessment of Kermani’s literary work by Torsten Hoffmann == Torsten Hoffmann, a literary scholar, a professor at the University of Stuttgart, and a recognized and long-standing expert on Kermani's extensive literary work, classifies Kermani’s narrative work as follows: Most of Kermani’s literary texts draw on an auto-fictionalapproach (in his most extensive novel, „Dein Name“ [Your Name], the protagonist is also named “Navid Kermani”). Furthermore, they are characterizing by a particular interest in fundamental human experiences such as birth, love, and death, along with a programmatic combination of (sometimes drastic) everydayness with an affinity for art (including literature, music, film, and the visual arts) and religiosity. The boundaries between his works of fiction and works more commonly regarded as nonfiction (such as „Ungläubiges Staunen“ (Wonder Beyond Belief) or „Jeder soll von da, wo er ist, einen Schritt näher kommen“ (Everyone, Wherever You Are, Come One Step Closer) and travelogues are fluid. For while Kermani’s nonfiction books often employ literary narrative techniques, conversely, many of his works of fiction contain essayistic passages.
=== Mass change === Mass change (decrease) in bound systems, particularly atomic nuclei, has also been termed mass defect, mass deficit, or mass packing fraction. The difference between the unbound system calculated mass and experimentally measured mass of nucleus (mass change) is denoted as Δm. It can be calculated as follows:
4He* → n + 3He + 3.3 MeV (ratio=50%) 4He* → p + 3H + 4.0 MeV (ratio=50%) 4He* → 4He + γ + 24 MeV (ratio=10−6) Only about one in a million of the intermediaries take the third pathway, making its products very rare compared to the other paths. This result is consistent with the predictions of the Bohr model. If 1 watt (6.242 × 1018 eV/s) were produced from ~2.2575 × 1011 deuteron fusions per second, with the known branching ratios, the resulting neutrons and tritium (3H) would be easily measured. Some researchers reported detecting 4He but without the expected neutron or tritium production; such a result would require branching ratios strongly favouring the third pathway, with the actual rates of the first two pathways lower by at least five orders of magnitude than observations from other experiments, directly contradicting both theoretically predicted and observed branching probabilities. Those reports of 4He production did not include detection of gamma rays, which would require the third pathway to have been changed somehow so that gamma rays are no longer emitted. The known rate of the decay process together with the inter-atomic spacing in a metallic crystal makes heat transfer of the 24 MeV excess energy into the host metal lattice prior to the intermediary's decay inexplicable by conventional understandings of momentum and energy transfer, and even then there would be measurable levels of radiation. Also, experiments indicate that the ratios of deuterium fusion remain constant at different energies.
==== Re-release in Japan ==== Darbar was re-released as Dalbar Revenge, in Japan's theatre chain MKC Plex on 16 July 2021, and ran with a full house for a week. The film was supposed to be screened until 21 July but its run was extended to the end of July. According to some reports, it ran until August in some cities. According to Sify: Multiple shows are being added for [Darbar] in Japan. Huge demand for tickets there. Distributors are very happy with the profits ... According to reports, the movie has created quite a rage among fans. This is likely to be screened in more cities such as Kyoto, Nagoya, and Niigata, among others. According to media reports, Darbar grossed ¥230 million in Japan. The film earned approximately ₹15 crore. Darbar is the second-highest-grossing film for Rajinikanth in Japan after Muthu and fourth-highest grossing Indian film in Japan.
Sources: en.wikipedia.org
== Taxonomy and phylogeny == Pholcus phalangioides was first described in 1775 by the Swiss entomologist Johann Kaspar Füssli. A member of the genus Pholcus in the family Pholcidae, P. phalangioides shares ancestry with roughly 1,340 similar cellar-spiders. All of these spiders are known for their characteristic long legs, which can range from 5 to 6 times the size of their bodies. This is not to be confused with organisms with similar physical appearances, such as the crane fly – an insect – and harvestmen of the arachnid order Opiliones.
The harvesting, processing, and consuming of seafoods are ancient practices with archaeological evidence dating back well into the Paleolithic. Findings in a sea cave at Pinnacle Point in South Africa indicate Homo sapiens (modern humans) harvested marine life as early as 165,000 years ago, while the Neanderthals, an extinct human species contemporary with early Homo sapiens, appear to have been eating seafood at sites along the Mediterranean coast beginning around the same time. Isotopic analysis of the skeletal remains of Tianyuan man, a 40,000-year-old anatomically modern human from eastern Asia, has shown that he regularly consumed freshwater fish. Archaeology features such as shell middens, discarded fish bones, and cave paintings show that sea foods were important for survival and consumed in significant quantities. During this period, most people lived a hunter-gatherer lifestyle and were, of necessity, constantly on the move. However, early examples of permanent settlements (though not necessarily permanently occupied), such as those at Lepenski Vir, were almost always associated with fishing as a major source of food. The ancient river Nile was full of fish; fresh and dried fish were a staple food for much of the population. The Egyptians had implements and methods for fishing and these are illustrated in tomb scenes, drawings, and papyrus documents. Some representations hint at fishing being pursued as a pastime.
== Epigenetic effects == The honey bee queens and workers represent one of the most striking examples of environmentally controlled phenotypic polymorphism. Even if two larvae had identical DNA, one raised to be a worker, the other a queen, the two adults would be strongly differentiated across a wide range of characteristics including anatomical and physiological differences, longevity, and reproductive capacity. Queens constitute the female sexual caste and have large active ovaries, whereas female workers have only rudimentary, inactive ovaries and are functionally sterile. The queen–worker developmental divide is controlled epigenetically by differential feeding with royal jelly; this appears to be due specifically to the protein royalactin. A female larva destined to become a queen is fed large quantities of royal jelly; this triggers a cascade of molecular events resulting in development of a queen. It has been shown that this phenomenon is mediated by an epigenetic modification of DNA known as CpG methylation. Silencing the expression of an enzyme that methylates DNA in newly hatched larvae led to a royal jelly-like effect on the larval developmental trajectory; the majority of individuals with reduced DNA methylation levels emerged as queens with fully developed ovaries. This finding suggests that DNA methylation in honey bees allows the expression of epigenetic information to be differentially altered by nutritional input.
=== Books === In September 2019, Sinclair published Lifespan: Why We Age – and Why We Don't Have To co-written with journalist Matthew LaPlante and translated into 18 languages. This was also released as an audiobook on Audible and read by Sinclair. Sinclair broadly discusses his longevity practices on social media and includes them in his book. They include daily doses of nicotinamide mononucleotide (NMN) and resveratrol, which Sinclair claims are activators of SIRT1.
uridine (U, Urd) One of the four standard nucleosides used in RNA molecules, consisting of a uracil base with its N9 nitrogen bonded to the C1 carbon of a ribose sugar. In DNA, uridine is replaced with thymidine.
Sources: en.wikipedia.org
=== Fatty acid uptake === Long chain fatty acid uptake is mediated by several transporters, including FAT (fatty acid translocase)/CD36. CD36 deletion rescues lipotoxic cardiomyopathy. FAT/CD36 may be controlled by insulin and AMPK. Increased transport coupled to the formation of the CoA derivatives and the resulting AMPK activation should ensure efficient fatty acid uptake and metabolism.
=== Neuronal replacement === Stem-cell therapy is used to replace damaged neurons by transplantation of stem cells into affected regions of the brain. Experiments in rat and mouse models of HD have yielded positive results. Stem cells are also used to study HD in the laboratory.
The primary function of muscle tissue is contraction. The three types of muscle tissue (skeletal, cardiac and smooth) have significant differences. However, all three use the movement of actin against myosin to create contraction.
Performance-enhancing substances (PESs), also known as performance-enhancing drugs (PEDs), are substances that are used to improve any form of activity performance in humans. Many substances, such as anabolic steroids, can be used to improve athletic performance and build muscle, which in most cases is considered cheating by organized athletic organizations. This usage is often referred to as doping. Athletic performance-enhancing substances are sometimes referred to as ergogenic aids. Cognitive performance-enhancing drugs, commonly called nootropics, are sometimes used by students to improve academic performance. Performance-enhancing substances are also used by military personnel to enhance combat performance.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.